Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
|Articles|August 1, 1999
Supplements and Featured Publications
- Vascular Compliance: Clinical and Managed Care Issues
- Volume 5
- Issue 12 Suppl
Perindopril: Clinical Profile of a Unique ACE Inhibitor
Author(s)Joel M. Neutel, MD
Advertisement
Articles in this issue
about 27 years ago
Participating Facultyabout 27 years ago
Introductionabout 27 years ago
Can Arterial Stiffness be Reversed? And If So, What are the Benefits?about 27 years ago
Issues in Vascular Complianceabout 27 years ago
Selected Abstractsabout 27 years ago
BibliographyAdvertisement
Related to this article
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
FDA Approves First Symptomatic Dermographism Treatment
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5